Eli Lilly and Company $LLY Shares Sold by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 62.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 934 shares of the company’s stock after selling 1,546 shares during the quarter. Patton Albertson Miller Group LLC’s holdings in Eli Lilly and Company were worth $1,004,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. Marmo Financial Group LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $207,000. Ponta Wealth Partners LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $1,276,000. Manske Wealth Management increased its holdings in shares of Eli Lilly and Company by 6.3% in the fourth quarter. Manske Wealth Management now owns 476 shares of the company’s stock valued at $512,000 after purchasing an additional 28 shares during the period. Total Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $255,000. Finally, Indivisible Partners acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $13,005,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.8%

Eli Lilly and Company stock opened at $948.01 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a market cap of $892.78 billion, a PE ratio of 33.68, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48. The stock’s 50 day moving average price is $943.90 and its 200 day moving average price is $990.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.68 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 24.58%.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Bank of America dropped their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. Daiwa Securities Group boosted their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a report on Tuesday, February 10th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.